MDXG

About MDXG

MiMedx Group, Inc. is a transformational placental biologics company, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.